Hemorrhagic Fever, Ebola: Clinical Trials

103 trials for Hemorrhagic Fever, Ebola, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

68 completed, 11 unknown, 7 terminated, 5 not yet recruiting. 46 Phase 1, 28 Phase 2, 14 Phase 3, 4 Phase 4, 2 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 146Completed 34, Terminated 5, Unknown 4, Withdrawn 2, Recruiting 1
Phase 228Completed 21, Not yet recruiting 2, Unknown 2, Withdrawn 2, Active not recruiting 1
Phase 314Completed 7, Not yet recruiting 2, Withdrawn 2, Recruiting 1, Terminated 1, Unknown 1
Phase 44Active not recruiting 1, Completed 1, Recruiting 1, Unknown 1
Not applicable2Unknown 2

Follow Hemorrhagic Fever, Ebola: new trials by email Literature Review of Hemorrhagic Fever, Ebola trials Research Report on Hemorrhagic Fever, Ebola

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
Ervebo, Inmazeb - Ebola Virus Disease
Phase 2Not yet recruitingANRS, Emerging Infectious Diseases1322027-01-012026-01-22
Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - DRC
DECIPHER bioassay - Ebola Hemorrhagic Fever
Not yet recruitingInstitute of Tropical Medicine, Belgium1002027-01-012026-07-07
Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA
FORTIFIEDx and DECIPHER bioassays - Ebola Hemorrhagic Fever, Lassa Hemorrhagic Fever
Not yet recruitingInstitute of Tropical Medicine, Belgium1502027-01-012026-07-02
Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo
Candidate BDBV vaccine, Active comparator - Ebola Hemorrhagic Fever, Bundibugyo Virus Disease
Phase 2 / Phase 3Not yet recruitingJean-Pierre Van geertruyden36202026-10-202026-10-05
BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies
ERVEBO Vaccination - Ebola, Bundibugyo Virus Disease (BVD)
Phase 4RecruitingEpicentre200002026-09-192026-10-29
EBOla Post-Exposure Prophylaxis
Ervebo, Inmazeb - Ebola Virus Disease
Phase 3Not yet recruitingANRS, Emerging Infectious Diseases1602026-09-012026-01-22
Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure
ERVEBO® (rVSV∆G-ZEBOV-GP) - Ebola Vaccine
Phase 3WithdrawnUniversitätsklinikum Hamburg-Eppendorf2026-06-012026-06-04
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
rVSVΔG-SUDV-GP, Placebo - Sudan Virus Disease
Phase 1RecruitingInternational AIDS Vaccine Initiative1122026-05-082026-09-21
REVIVE (Response to the Ebola Virus Vaccine)
rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO) - Ebola Virus Disease
Phase 4Active not recruitingTulane University402025-12-012026-06-04
Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC
Zabdeno® booster, Ervebo® booster - Ebola Virus Disease
Phase 3RecruitingInstitute of Tropical Medicine, Belgium6242025-02-252025-03-18
Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in Liberia
Ebola, Post-Acute Ebola Syndrome
CompletedNational Institute of Neurological Disorders and Stroke (NINDS)3282025-02-142026-10-29
Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses
BioNTech - Pfizer COVID-19 vaccine, 1mL saline solution, rVSV∆G-ZEBOV-GP - Ebola Virus Disease, COVID-19
Phase 4UnknownUniversity of Birmingham722024-10-012024-09-19
Immunology of Ebola Vaccine
Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP), Deuterium Labeled Water - Ebola Virus Disease
Phase 2Active not recruitingEmory University302024-08-062026-01-22
Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda
Ebola+D intervention - Ebola Virus Disease
Not applicableUnknownMRC/UVRI and LSHTM Uganda Research Unit10002023-09-222023-10-23
Community Preparedness for Outbreak Response and Readiness for Ebola Vaccination in Liberia
Community Clusters - Ebola Virus Disease
UnknownUL-PIRE Africa Center15002023-06-012023-06-05
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
Ad26.ZEBOV, MVA-BN-Filo - Virus Diseases, Hemorrhagic Fever, Ebola
Phase 2CompletedLondon School of Hygiene and Tropical Medicine1332022-09-192025-05-11
Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III
Ebola Virus Disease
CompletedNational Institute of Allergy and Infectious Diseases (NIAID)2032022-08-252025-07-18
A Study in Tanzania of a New Vaccine Against Two Types of Ebola
ChAdOx1 biEBOV - Ebola
Phase 1UnknownUniversity of Oxford762022-03-302023-02-08
A Study of a New Vaccine Against Two Types of Ebola
ChAdOx1 biEBOV - Ebola
Phase 1CompletedUniversity of Oxford262021-11-112025-04-04
Prophylaxis Vaccine Antibodies Ebola
ansuvimab, Ervebo - Ebola Virus Disease
Phase 2UnknownANRS, Emerging Infectious Diseases2502021-10-172021-10-15

Showing 20 of 103. Sign in to see all of them.

Narrower conditions

Hemorrhagic Fevers, Viral (18)  ·  Filoviridae Infections (5)  ·  Marburg Virus Disease (4)  ·  Virus Diseases (4)  ·  Acquired Immunodeficiency Syndrome (3)  ·  RNA Virus Infections (3)  ·  Communicable Diseases, Emerging (2)  ·  Infections (2)  ·  Mononegavirales Infections (2)  ·  Acquired angioedema (1)  ·  Angioedemas, Hereditary (1)  ·  Bacterial Infections (1)  ·  COVID-19 (1)  ·  Chikungunya Fever (1)

Broader conditions

Infections (101)  ·  Mononegavirales Infections (101)  ·  RNA Virus Infections (100)  ·  Virus Diseases (99)  ·  Filoviridae Infections (98)  ·  Hemorrhagic Fevers, Viral (85)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Animal Diseases (4)  ·  Communicable Diseases (4)  ·  Monkey Diseases (4)  ·  Pathologic Processes (4)  ·  Primate Diseases (4)  ·  Blood-Borne Infections (3)  ·  Disease Attributes (3)  ·  Genital Diseases (3)

Interventions

Ebola Vaccines (4)  ·  Saline Solution (4)  ·  ansuvimab (3)  ·  atoltivimab, maftivimab, and odesivimab-ebgn drug combination (3)  ·  MenACWY (2)  ·  ZMapp (2)  ·  favipiravir (2)  ·  remdesivir (2)  ·  Amiodarone (1)  ·  Atorvastatin (1)  ·  Azithromycin (1)  ·  BNT162 Vaccine (1)  ·  COVID-19 Serotherapy (1)  ·  Chickenpox Vaccine (1)  ·  Deuterium Oxide (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (20)  ·  University of Oxford (8)  ·  Janssen Vaccines & Prevention B.V. (7)  ·  Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (6)  ·  Institute of Tropical Medicine, Belgium (5)  ·  London School of Hygiene and Tropical Medicine (5)  ·  ANRS, Emerging Infectious Diseases (3)  ·  Jiangsu Province Centers for Disease Control and Prevention (3)  ·  Arbutus Biopharma Corporation (2)  ·  Clinical Research Management, Inc. (2)  ·  Epicentre (2)  ·  Institut National de la Santé Et de la Recherche Médicale, France (2)  ·  MRC/UVRI and LSHTM Uganda Research Unit (2)  ·  Sarepta Therapeutics, Inc. (2)  ·  University of Maryland, Baltimore (2)

Countries

United States (28)  ·  Democratic Republic of the Congo (11)  ·  Sierra Leone (11)  ·  Liberia (10)  ·  Uganda (10)  ·  Guinea (9)  ·  United Kingdom (7)  ·  Russia (6)  ·  Kenya (5)  ·  China (3)  ·  Germany (3)  ·  Mali (3)  ·  Tanzania (3)  ·  Burkina Faso (2)  ·  Canada (2)

Top investigators

Deborah Watson-Jones, PhD (3)  ·  Richard T Davey, M.D. (3)  ·  Alison Heald, MD (2)  ·  Bailah Leigh, MD (2)  ·  Bridgette J Billioux, M.D. (2)  ·  Julie E Ledgerwood, D.O. (2)  ·  Kawsar Talaat, MD (2)  ·  Konstantin Zhdanov, MD, PhD (2)  ·  Abdoul Habib Beavogui (1)  ·  Adrian V Hill (1)  ·  Ali Ellebedy, PhD (1)  ·  Alie H Wurie (1)  ·  Alimou Camara, Dr. (1)  ·  Angela Huttner, MD (1)

Results publications

PMID 28647166, PMID 25426834, PMID 25830326, PMID 26546548, PMID 26659569, PMID 28017642, PMID 30407513, PMID 30855742, PMID 34930928, PMID 38603720, PMID 11009541, PMID 11395204, PMID 14741143, PMID 1538192, PMID 15577929, PMID 15983268, PMID 16375711, PMID 17548132, PMID 17553602, PMID 17762021, PMID 22342706, PMID 23125444, PMID 23170176, PMID 24738640, PMID 25225676, PMID 25540891, PMID 25558097, PMID 25629663, PMID 25817373, PMID 25955968, PMID 25974635, PMID 26725120, PMID 26725450, PMID 26735992, PMID 26768569, PMID 26768570, PMID 26768572, PMID 26930627, PMID 27004234, PMID 27046271, PMID 27382077, PMID 27732819, PMID 27959686, PMID 28231247, PMID 28434944, PMID 28708962, PMID 29627147, PMID 29659889, PMID 29788339, PMID 29788340

NIH funding

2019 (2), 2014 (1), 2015 (1)